盐酸纳呋拉啡:从适应症到禁忌症的全面解读

Introduction: Nafurapine hydrochloride is a selective kappa opioid receptor agonist, used to treat specific types of pruritus in dialysis patients and patients with chronic liver disease. Nafurafine hydrochloride is the world's first highly selective kappa opioid receptor agonist developed by Toray Industries and has been marketed in Japan by Torii Pharmaceutical since March 2009 for the treatment of itching in hemodialysis patients. It controls itching based on a different mechanism than antihistamines and anti-allergy drugs, and is effective for itching that cannot be controlled by existing treatments.

Indications of nalfurapine hydrochloride

It is mainly used to improve unbearable skin itching that occurs during hemodialysis or peritoneal dialysis. In addition to dialysis patients, nalfurapine hydrochloride is also suitable for patients with chronic liver disease who suffer from itching symptoms.

Contraindications of nalfuraphine hydrochloride

It is prohibited for those who are allergic to nalfuraphine hydrochloride or its components to avoid allergic reactions. If the patient has severe (Child-Pugh Class C) liver injury, the risks and benefits should be evaluated to determine whether nalfurapine hydrochloride can be used, and the patient's status should be closely observed during the medication.

Effectiveness results

Oral administration of 2.5 μg and 5 μg of nalfurapine hydrochloride for the treatment of refractory pruritus in hemodialysis patients was observed within the first 7 days of treatment and continued during the 52-week treatment period. Nafurafine hydrochloride is also effective in the treatment of conventionally refractory pruritus in peritoneal dialysis patients. In addition, 2.5 μg of nalfuraphine hydrochloride and 5 μg of nalfuraphine hydrochloride are effective in treating refractory pruritus in patients with chronic liver disease within 7 days of medication. In all clinical trials, most adverse drug reactions (ADRs) were mild and resolved quickly, with no clinical safety concerns. After 52 weeks of treatment, the hemodialysis patients showed no physical or psychological dependence, indicating that there is no risk of addiction. In summary, oral administration of 2.5 μg and 5 μg of nalfurapine hydrochloride is safe and effective in the treatment of refractory pruritus in patients with hemodialysis or peritoneal dialysis and patients with chronic liver disease.

Storage method

Unused nalfurapine hydrochloride should be sealed and stored in the original packaging to avoid storage in a humid environment. Pay attention to the expiration date on the drug packaging and use it within the specified expiration date.